<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE300nnn/GSE300663/</Other></files><type>primary</type></body><statusCodeValue>200</statusCodeValue><statusCode>OK</statusCode></file_versions><scores/><additional><omics_type>Genomics</omics_type><species>Homo sapiens</species><gds_type>Genome binding/occupancy profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300663</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Histamine H4 receptor antagonists prevent receptor-mediated and EBV-induced B cell proliferation [ATAC-seq]</name><description>Epstein-Barr virus (EBV) infects over 90% of the global population and establishes lifelong latency in memory B cells. In healthy individuals, this latent infection is typically kept in check by the immune system. However, in immunosuppressed patients, EBV can reactivate, leading to uncontrolled B cell proliferation and development of post-transplant lymphoproliferative disorders (PTLD)—a potentially fatal complication. In this study, we demonstrate that selective antagonists of the histamine H4 receptor (H4R), a G protein-coupled receptor expressed in immune cells, potently suppress B cell activation and proliferation triggered by antigenic stimuli or EBV infection. Notably, the lead compound A943931 inhibited transcriptional programs critical for B cell activation, including downregulation of key metabolic genes, resulting in profound suppression of both glycolysis and oxidative phosphorylation. A943931 also blocked EBV-driven B cell immortalization and impaired energy metabolism in lymphoblastoid cell lines, albeit to a lesser extent than in receptor-stimulated B cells. In vivo, A943931 suppressed tumor growth in Daudi Burkitt lymphoma xenografts and prevented B cell lymphoma development in EBV-infected humanized mice. These findings reveal a novel immunometabolic vulnerability of EBV-infected B cells and position H4R antagonists as promising therapeutic candidates for EBV-associated lymphoproliferative disorders, including PTLD and potentially EBV-linked autoimmune diseases.</description><dates><publication>2026/06/29</publication></dates><accession>GSE300663</accession><cross_references><GSM>GSM9065937</GSM><GSM>GSM9065926</GSM><GSM>GSM9065927</GSM><GSM>GSM9065938</GSM><GSM>GSM9065924</GSM><GSM>GSM9065935</GSM><GSM>GSM9065936</GSM><GSM>GSM9065925</GSM><GSM>GSM9065933</GSM><GSM>GSM9065934</GSM><GSM>GSM9065923</GSM><GSM>GSM9065942</GSM><GSM>GSM9065931</GSM><GSM>GSM9065932</GSM><GSM>GSM9065939</GSM><GSM>GSM9065928</GSM><GSM>GSM9065929</GSM><GSM>GSM9065940</GSM><GSM>GSM9065941</GSM><GSM>GSM9065930</GSM><GPL>18573</GPL><GSE>300663</GSE><taxon>Homo sapiens</taxon><PMID>[42140525]</PMID></cross_references></HashMap>